These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

699 related articles for article (PubMed ID: 12743807)

  • 1. Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis.
    Nok AJ
    Parasitol Res; 2003 May; 90(1):71-9. PubMed ID: 12743807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current chemotherapy of human African trypanosomiasis.
    Docampo R; Moreno SN
    Parasitol Res; 2003 Jun; 90 Supp 1():S10-3. PubMed ID: 12811544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The treatment of human African trypanosomiasis.
    Pépin J; Milord F
    Adv Parasitol; 1994; 33():1-47. PubMed ID: 8122565
    [No Abstract]   [Full Text] [Related]  

  • 4. [Current therapy of trypanosomiasis].
    Doua F; Boa Yapo F
    Bull Soc Pathol Exot; 1994; 87(5):337-40. PubMed ID: 7496197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vivo resistance to strains of Trypanosoma rhodesiense, Mozambique, 1985].
    Pérez Martín O; Lastre González M; Urban M; Shwalbach J
    Rev Cubana Med Trop; 1991; 43(3):189-93. PubMed ID: 9768188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diamidines for human African trypanosomiasis.
    Paine MF; Wang MZ; Generaux CN; Boykin DW; Wilson WD; De Koning HP; Olson CA; Pohlig G; Burri C; Brun R; Murilla GA; Thuita JK; Barrett MP; Tidwell RR
    Curr Opin Investig Drugs; 2010 Aug; 11(8):876-83. PubMed ID: 20721830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis.
    Wenzler T; Yang S; Braissant O; Boykin DW; Brun R; Wang MZ
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5330-43. PubMed ID: 23959303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metronidazole and suramin combination in the treatment of arsenical refractory Rhodesian sleeping sickness--a case study.
    Foulkes JR
    Trans R Soc Trop Med Hyg; 1996; 90(4):422. PubMed ID: 8882195
    [No Abstract]   [Full Text] [Related]  

  • 9. The phenomenon of treatment failures in Human African Trypanosomiasis.
    Brun R; Schumacher R; Schmid C; Kunz C; Burri C
    Trop Med Int Health; 2001 Nov; 6(11):906-14. PubMed ID: 11703845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human African trypanosomiasis: potential therapeutic benefits of an alternative suramin and melarsoprol regimen.
    Jennings FW; Rodgers J; Bradley B; Gettinby G; Kennedy PG; Murray M
    Parasitol Int; 2002 Dec; 51(4):381-8. PubMed ID: 12421636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo evaluation of 28DAP010, a novel diamidine for treatment of second-stage African sleeping sickness.
    Wenzler T; Yang S; Patrick DA; Braissant O; Ismail MA; Tidwell RR; Boykin DW; Wang MZ; Brun R
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4452-63. PubMed ID: 24867978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story.
    Baker N; de Koning HP; Mäser P; Horn D
    Trends Parasitol; 2013 Mar; 29(3):110-8. PubMed ID: 23375541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ever-increasing complexities of diamidine and arsenical crossresistance in African trypanosomes.
    de Koning HP
    Trends Parasitol; 2008 Aug; 24(8):345-9. PubMed ID: 18599351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A returning traveller with fever, facial swelling, and skin lesions.
    Richter J; Göbels S; Göbel T; Westenfeld R; Müller-Stöver I; Häussinger D
    BMJ; 2012 Mar; 344():e2092. PubMed ID: 22442353
    [No Abstract]   [Full Text] [Related]  

  • 15. Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure rate.
    Maina N; Maina KJ; Mäser P; Brun R
    Acta Trop; 2007; 104(2-3):84-90. PubMed ID: 17765860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential virulence of Trypanosoma brucei rhodesiense isolates does not influence the outcome of treatment with anti-trypanosomal drugs in the mouse model.
    Ndung'u K; Murilla GA; Thuita JK; Ngae GN; Auma JE; Gitonga PK; Thungu DK; Kurgat RK; Chemuliti JK; Mdachi RE
    PLoS One; 2020; 15(11):e0229060. PubMed ID: 33151938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapses following treatment of early-stage Trypanosoma brucei gambiense sleeping sickness with a combination of pentamidine and suramin.
    Pépin J; Khonde N
    Trans R Soc Trop Med Hyg; 1996; 90(2):183-6. PubMed ID: 8761585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy against human African trypanosomiasis: is there a road to success?
    Burri C
    Parasitology; 2010 Dec; 137(14):1987-94. PubMed ID: 20961469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy of sleeping sickness.
    Cent Afr J Med; 1979 Nov; 25(11):251. PubMed ID: 544029
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment perspectives for human African trypanosomiasis.
    Bouteille B; Oukem O; Bisser S; Dumas M
    Fundam Clin Pharmacol; 2003 Apr; 17(2):171-81. PubMed ID: 12667227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.